Subjects with any previously untreated or concurrent cancer that is distinct in primary site or histology except cervical cancer in-situ, treated basal cell carcinoma, or superficial bladder tumor; subjects surviving a cancer that was curatively treated and without evidence of disease for more than  years before registration are allowed; all cancer treatments must be completed at least  years prior to study registration
Previous or concurrent cancer within  years prior to treatment start EXCEPT for curatively treated cervical cancer in situ, non-melanoma skin cancer, superficial bladder tumors (Ta [non-invasive tumor], Tis [carcinoma in situ] and T [tumor invades lamina propria])
Subjects with any previously untreated or concurrent cancer that is distinct in primary site or histology from breast cancer except cervical cancer in-situ, treated localized basal cell carcinoma, Gleason score  prostate cancer or superficial bladder tumor; subjects surviving a cancer that was curatively treated and without evidence of disease for more than  years before randomization are allowed; all cancer treatments for another malignancy must be completed at least  years prior to study entry (i.e., signature date of the informed consent form)
Subjects with any previously untreated or concurrent cancer that is distinct in primary site or histology from breast cancer except cervical cancer in-situ, treated basal cell carcinoma, or superficial bladder tumor; subjects surviving a cancer that was curatively treated and without evidence of disease for more than  years before randomization are allowed; all cancer treatments must be completed at least  years prior to study entry (i.e., signature date of the informed consent form)
Subjects with any previously untreated and concurrent cancer that is distinct in primary site or histology from HCC except cervical cancer in-situ, treated nonmelanoma skin cancers, localized prostate cancer not requiring systemic therapy undergoing surveillance, or superficial bladder tumor; subjects surviving a cancer that was curatively treated and without evidence of disease for more than  years before enrollment are allowed provided that cancer therapy was completed at least  years prior to study entry (date of the informed consent form)
Previous or concurrent cancer within  years prior to treatment start EXCEPT for curatively treated cervical cancer in situ, non-melanoma skin cancer, superficial bladder tumors (Ta [non-invasive tumor], Tis [carcinoma in situ] and T [tumor invades lamina propria])
Patients with any previously untreated or concurrent cancer that is distinct in primary site or histology except cervical cancer in-situ, treated ductal carcinoma in situ of the breast, curatively treated nonmelanoma skin carcinoma, noninvasive aerodigestive neoplasms, or superficial bladder tumor; subjects surviving a cancer that was curatively treated and without evidence of disease for more than  years before registration are allowed; all cancer treatments must be completed at least  years prior to registration
Previously untreated or concurrent cancer that is distinct in primary site or histology except cervical cancer in-situ, treated ductal carcinoma in situ of the breast, curatively treated non-melanoma skin carcinoma, noninvasive aerodigestive neoplasms or superficial bladder tumor; subjects surviving a cancer that was curatively treated and without evidence of disease for more than  years before registration are allowed; all cancer treatments for concurrent cancers must be completed at least  years prior to registration
Previous or concurrent cancer that is distinct in primary site or histology within  years; exceptions: curatively treated\r\n* Cervical cancer in situ\r\n* Non-melanoma skin cancer\r\n* Superficial bladder tumors (non-invasive tumor [Ta], carcinoma in situ [Tis] and tumor invades lamina propria [T])
Previous or concurrent cancer within  years prior to treatment start EXCEPT for curatively treated cervical cancer in situ, non-melanoma skin cancer and superficial bladder tumors (Ta [non-invasive tumor], Tis [carcinoma in situ] and T [tumor invades lamina propria])
Previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study EXCEPT cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors ( Ta, Tis &T) or any cancer curatively treated >  years prior to study entry.
Patients who have a previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study, except\r\n* Cervical carcinoma in situ, non-melanoma skin cancer, superficial noninvasive bladder tumors, ductal carcinoma in situ (DCIS) or any previous cancer curatively treated > years before the start of anetumab ravtansine
Previous or concurrent cancer that is distinct in primary site or histology from cancer of primary site =<  years prior to randomization EXCEPT for curatively treated cervical cancer in situ, melanoma in situ, non-melanoma skin cancer and superficial bladder tumors [Ta (non-invasive tumor), Tis (carcinoma in situ) and T (tumor invades lamina propria)]; Note: All cancer treatments for those distinct in a primary site other than cancer of origin must be completed >=  years prior to randomization
Subjects with any previously untreated or concurrent cancer that is distinct in primary site or histology from carcinoid or pancreatic islet cancer except cervical cancer in-situ, treated basal cell carcinoma, or superficial bladder tumor; subjects surviving a cancer that was curatively treated and without evidence of disease for more than  years before randomization are allowed; all cancer treatments must be completed at least  years prior to study entry (i.e., signature date of the informed consent form)
Previous or concurrent history of malignancies within  years prior to study treatment except for curatively treated:\r\n* Cervical carcinoma in situ\r\n* Non-melanoma skin cancer\r\n* Superficial bladder cancer (Ta [non-invasive tumor], Tis [carcinoma in situ] and T [tumor invades lamina propria])
Patients with any previously untreated or concurrent cancer that is distinct in primary site or histology from biliary tract cancer except cervical cancer in-situ, treated basal cell carcinoma, or superficial bladder tumor; patients surviving a cancer that was curatively treated and without evidence of disease for more than  years prior to registration are allowed; all cancer treatments must be completed at least  years prior to prior to registration)
Subjects who have a previous or concurrent cancer that is distinct in primary site or histology from lung adenocarcinoma, except cervical carcinoma in situ, treated basal cell carcinoma, superficial noninvasive bladder tumors or any previous cancer curatively treated <  years before the start of study treatment
Patients with non-HCC malignancy except those with DCIS (ductal carcinoma in situ), cervical cancer in-situ, basal cell or superficial bladder tumor; patients surviving a cancer that was curatively treated and without evidence of recurrence for more than  years before randomization are allowed
Recent history of prior cancer except cervical cancer in-situ, treated basal cell carcinoma, or superficial bladder tumor; subjects surviving a cancer that was curatively treated and without evidence of disease for more than  years before enrollment are allowed
Previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study, except cervical carcinoma in situ, treated basal cell carcinoma, superficial noninvasive bladder tumors or any previous cancer curatively treated ?  years before the start of anetumab ravtansine
Subjects with any previously untreated or concurrent cancer that is distinct in primary site or histology from breast cancer except cervical cancer in-situ, treated basal cell carcinoma, or superficial bladder tumor. Subjects surviving a cancer that was curatively treated and without evidence of disease for more than  years before randomization are allowed. All cancer treatments must be completed at least  years prior to study entry (ie, signature date of the informed consent form).
Have a previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study, except cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors (Ta and Tis [carcinoma in situ]) or any previous cancer curatively treated < years ago.
Subjects who have a previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study, or any previous cancer curatively treated > years before the start of study Treatment.
Subjects with any previously untreated or concurrent cancer that is distinct in primary site or histology from pancreatic cancer except cervical cancer in-situ, treated basal cell carcinoma, or superficial bladder tumor; subjects surviving a cancer that was curatively treated and without evidence of disease for more than  years before randomization are allowed; all cancer treatments must be completed at least  years prior to study entry (i.e., signature date of the informed consent form)
Previous or concurrent cancer that is distinct in primary site or histology from colorectal cancer within  years prior to randomization EXCEPT for curatively treated cervical cancer in situ, non-melanoma skin cancer and superficial bladder tumors (Ta [non-invasive tumor], Tis [carcinoma in situ] and T [tumor invades lamina propria]); note: all cancer treatments for cancers that were distinct in a primary site other than colorectal must be completed at least  years prior to randomization (i.e., signature date of the informed consent form)
No active malignancy except for nonmelanoma skin cancer or in situ cervical cancer; subjects surviving a cancer that was curatively treated and without evidence of disease for more than  years before the trial are allowed; all cancer treatments must be completed at least  years prior to study entry (i.e., signature date of the informed consent form)
Previous or concurrent cancer other than HCC unless without evidence of disease for  or more years prior to entry, except cervical cancer in-situ, treated basal cell carcinoma, or superficial bladder tumor
Subjects with any previously untreated or concurrent cancer that is distinct in primary site or histology from breast cancer except cervical cancer in-situ, treated basal cell carcinoma, or superficial bladder tumor; subjects surviving a cancer that was curatively treated and without evidence of disease for more than  years before randomization are allowed; all cancer treatments must be completed at least  years prior to study entry (i.e., signature date of the informed consent form)
Subjects with any previously untreated or concurrent cancer that is distinct in primary site or histology from HCC except cervical cancer in-situ, treated basal cell carcinoma, or superficial bladder tumor; subjects surviving a cancer that was curatively treated and without evidence of disease for more than  years before randomization are allowed; all cancer treatments must be completed at least  years prior to the first dose of sorafenib except for local treatments for cervical carcinoma in situ (CIS), basal cell carcinoma (BCC), and superficial bladder tumors
Previous or concurrent cancer that is distinct in primary site or histology from indolent B-cell NHL within  years prior to treatment start EXCEPT for curatively treated cervical cancer in situ, nonmelanoma skin cancer and superficial bladder tumors [Ta (non-invasive tumor), Tis (carcinoma in situ) and T (tumor invades lamina propria)].
Previous or concurrent cancer that is distinct in primary site or histology from indolent B-cell NHL within  years prior to treatment start EXCEPT for curatively treated cervical cancer in situ, nonmelanoma skin cancer and superficial bladder tumors [Ta (non-invasive tumor), Tis (carcinoma in situ) and T (tumor invades lamina propria)].
Previous or concurrent cancer that is distinct in primary site or histology from ASPS, LS, or SS within  years before enrollment except for curatively treated cervical cancer in situ, non-melanoma skin cancer and superficial bladder tumors (Ta, Tis and T).
Previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in the study EXCEPT cervical cancer in situ, treated basal cell carcinoma, superficial bladder tumors (Ta, Tis and T) or any cancer curatively treated >  years prior to study entry
Previous or concurrent cancer that is distinct in primary site or histology from colorectal cancer within  years prior to randomization EXCEPT for curatively treated cervical cancer in situ, non-melanoma skin cancer and superficial bladder tumors [Ta (Non-invasive tumor), Tis (Carcinoma in situ) and T (Tumor invades lamina propria)].
Subjects who have a previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study, except cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors (Ta and Tis) or any previous cancer curatively treated < years before the first dose of study drug
Subjects with any previously untreated or concurrent cancer that is distinct in primary site or histology from breast cancer except cervical cancer in-situ, treated basal cell carcinoma, or superficial bladder tumor; subjects surviving a cancer that was curatively treated and without evidence of disease for more than  years before enrollment are allowed; all cancer treatments must be completed at least  years prior to study entry (i.e., signature date of the informed consent form)
Subjects with any previously untreated or concurrent cancer that is distinct in primary site or histology except cervical cancer in-situ, treated basal cell carcinoma, or superficial bladder tumor; subjects surviving a cancer that was curatively treated and without evidence of disease for more than  years before randomization are allowed; all cancer treatments must be completed at least  years prior to start of study treatment
Subjects who are receiving treatment for a concurrent cancer that is distinct in primary site or histology from colorectal carcinoma, except any cancer in-situ, treated basal cell or squamous cell carcinoma, or superficial bladder tumor; subjects surviving a cancer that was curatively treated and without evidence of disease more than  year before randomization are allowed; all cancer treatments must be completed at least  year prior to start of study treatment
Have had prior or concurrent cancer distinct in primary site or histology from CRC within  years prior to randomization EXCEPT for curatively treated cervical cancer in situ, nonmelanoma skin cancer, Stage  intramucosal gastric cancer after endoscopic complete removal, or superficial bladder tumors classified as noninvasive tumor (Ta), carcinoma in situ (Tis), or tumor invades lamina propria (T).
Previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study, EXCEPT cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors [Ta, Tis and T] or any cancer curatively treated > years prior to study entry
Previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study except cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors (Ta, Tis & T) or any cancer curatively treated >  years prior to study entry
Previous or concurrent cancer that is distinct from HCC in primary site or histology, EXCEPT cervical carcinoma in situ, treated basal cell carcinoma, and superficial bladder tumors. Any cancer curatively treated more than  years prior to enrollment is permitted.
Phase  portion only: The subject has previous or concurrent cancer that is distinct in primary site or histology from NSCLC, except cervical carcinoma in situ, non-melanoma carcinoma of the skin or in situ carcinoma of the bladder. Any cancer curatively treated greater than  years prior to entry is permitted.
Subjects with any previously untreated or concurrent cancer unrelated to angiosarcoma; NOTE: exceptions include cervical cancer in-situ, treated basal cell carcinoma, or superficial bladder tumor; subjects surviving a cancer that was curatively treated and without evidence of disease for more than  years before registration are allowed; all treatments must have been completed at least  years prior to registration
Previous or concurrent cancer that is distinct in primary site or histology from breast cancer within  years prior to enrollment EXCEPT cervical cancer in situ, treated basal cell carcinoma, squamous cell carcinoma (SCC), as long as it is other than SCC involving skin of the head and/or neck, and superficial bladder tumors (Ta and Tis)
Any previously untreated or concurrent cancer that is distinct in primary site or histology from rectal cancer except cervical cancer in-situ, treated basal cell carcinoma, or superficial bladder tumor; subjects surviving a cancer that was curatively treated and without evidence of disease for more than  years before starting study drug are allowed; all cancer treatments must be completed at least  years prior to study entry (i.e., signature date of the informed consent form)
Patients with any previously untreated or concurrent cancer that is distinct in primary site or histology except cervical cancer in-situ, treated ductal carcinoma in situ of the breast, curatively treated nonmelanoma skin carcinoma, noninvasive aerodigestive neoplasms, or superficial bladder tumor; subjects surviving a cancer that was curatively treated and without evidence of disease for more than  years before registration are allowed; all cancer treatments must be completed at least  years prior to registration
Previous or coexisting cancer(s) distinct in primary site or histology from the cancer evaluated in this study EXCEPT:
